Preeclampsia Diagnostics

Global Preeclampsia Diagnostics Market to Reach US$3.5 Billion by 2030

The global market for Preeclampsia Diagnostics estimated at US$2.0 Billion in the year 2024, is expected to reach US$3.5 Billion by 2030, growing at a CAGR of 9.6% over the analysis period 2024-2030. Blood Tests, one of the segments analyzed in the report, is expected to record a 11.0% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the Urine Analysis segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$556.1 Million While China is Forecast to Grow at 13.4% CAGR

The Preeclampsia Diagnostics market in the U.S. is estimated at US$556.1 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$727.4 Million by the year 2030 trailing a CAGR of 13.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.7% and 8.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.

Global "Preeclampsia Diagnostics" Market – Key Trends & Drivers Summarized

Why Is Early Detection of Preeclampsia Gaining Clinical Priority?

Preeclampsia, a pregnancy complication marked by high blood pressure and potential organ damage, is a leading cause of maternal and neonatal morbidity worldwide. Early detection is critical, as untreated preeclampsia can escalate into life-threatening eclampsia or lead to premature births. As healthcare systems emphasize preventive prenatal care, diagnostic solutions for preeclampsia are receiving increased attention. Recent innovations include biomarker-based blood tests such as the sFlt-1/PlGF ratio, which enables early and reliable risk stratification. Point-of-care testing, integrated with portable analyzers and digital monitoring, is also emerging to support maternal care in both urban hospitals and remote clinics. These diagnostics are reshaping prenatal care by enabling timely intervention, thereby improving pregnancy outcomes and reducing the burden on intensive care services.

Who Are the Primary Stakeholders Advancing Diagnostic Capabilities?

Stakeholders in this evolving market include medical device manufacturers, obstetric care providers, academic researchers, and public health agencies. Diagnostic companies are developing assays with higher sensitivity and specificity to detect biomarkers in serum or plasma well before clinical symptoms appear. Hospitals and prenatal clinics are integrating these tests into standard care pathways to stratify high-risk pregnancies early on. Meanwhile, research institutions are exploring genomic and proteomic signatures for potential use in next-gen diagnostics. Global health agencies such as WHO and UNICEF are promoting maternal screening programs, particularly in low-income countries where preeclampsia-related mortality remains high. Collaborations between public entities and private players are expanding access to affordable diagnostics through subsidized programs and mobile health initiatives.

How Is the Global Market Adapting Across Regions?

Regional adoption of preeclampsia diagnostics varies based on healthcare infrastructure, maternal mortality rates, and regulatory readiness. North America and Western Europe are leading adopters, with established screening protocols and widespread insurance coverage supporting advanced testing. In Asia-Pacific, urban areas in China, Japan, and India are seeing rapid implementation of biomarker assays, driven by rising awareness and the expansion of maternal care infrastructure. Sub-Saharan Africa and parts of Latin America face challenges with access and affordability, but mobile clinics and telehealth platforms are bridging some gaps. Global initiatives are encouraging broader deployment of point-of-care diagnostic tools in these underserved regions, supported by donations and technology transfer from developed markets. These regional variations reflect the diverse maturity levels and urgency surrounding maternal health priorities.

What Is Driving the Expansion of Diagnostic Solutions?

The growth in the preeclampsia diagnostics market is driven by several factors rooted in clinical demand, healthcare policy, and technological evolution. Rising awareness of maternal health risks and early intervention benefits is pushing obstetricians and gynecologists to adopt biomarker-based tests as part of routine prenatal care. Advances in immunoassays, biosensors, and microfluidics have enabled the development of fast, accurate, and scalable diagnostic platforms. The increasing prevalence of high-risk pregnancies—due to factors such as older maternal age, obesity, and pre-existing hypertension—is amplifying the need for reliable screening. Supportive health policies and prenatal care incentives in both developed and developing countries are facilitating wider market access. Furthermore, partnerships between diagnostic developers and healthcare NGOs are enabling cost-effective deployment of testing solutions in resource-limited settings, thereby enhancing global penetration and impact.

SCOPE OF STUDY:

The report analyzes the Preeclampsia Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Test Type (Blood Tests, Urine Analysis, Other Test Types); Product Type (Instruments, Consumables); End-User (Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• Abbott Laboratories
• ACON Laboratories, Inc.
• Agilent Technologies, Inc.
• Bayer AG
• Beckman Coulter, Inc.
• Becton, Dickinson and Company
• bioMérieux SA
• Bio-Rad Laboratories, Inc.
• Diabetomics, Inc.
• DRG Instruments GmbH
• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• Metabolomic Diagnostics Ltd.
• Natera, Inc.
• PerkinElmer Inc.
• QuidelOrtho Corporation
• Sera Prognostics, Inc.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Trinity Biotech plc

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.